Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James Berman is active.

Publication


Featured researches published by James Berman.


Inflammatory Bowel Diseases | 2011

Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease

Millie D. Long; Wallace Crandall; Ian Leibowitz; Lynn Duffy; Fernando del Rosario; Sandra C. Kim; Mark Integlia; James Berman; John Grunow; Richard B. Colletti; Bess T. Schoen; Ashish S. Patel; Howard I. Baron; Esther J. Israel; George Russell; Sabina Ali; Hans H. Herfarth; Christopher Martin; Michael D. Kappelman

Background: Obesity is a significant public health threat to children in the United States. The aims were to: 1) Determine the prevalence of obesity in a multicenter cohort of children with inflammatory bowel disease (IBD); 2) Evaluate whether overweight and obese status is associated with patient demographics or disease characteristics. Methods: We used data from the ImproveCareNow Collaborative for pediatric IBD, a multicenter registry of children with IBD, collected between April 2007 and December 2009. Children ages 2–18 years were classified into body mass index (BMI) percentiles. Bivariate analyses and multivariate logistic regression were used to compare demographic and disease characteristics by overweight (BMI >85%) and obese (BMI >95%) status. Results: The population consisted of 1598 children with IBD. The prevalence of overweight/obese status in pediatric IBD is 23.6%, (20.0% for Crohns disease [CD] and 30.1% for ulcerative colitis [UC] and indeterminate colitis [IC]). African American race (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.10–2.48) and Medicaid insurance (OR 1.67, 95% CI 1.19–2.34) were positively associated with overweight/obese status. Prior IBD‐related surgery (OR 1.73, 95% CI 1.07–2.82) was also associated with overweight and obese status in children with CD. Other disease characteristics were not associated with overweight and obesity in children with IBD. Conclusions: Approximately one in five children with CD and one in three with UC are overweight or obese. Rates of obesity in UC are comparable to the general population. Obese IBD patients may have a more severe disease course, as indicated by increased need for surgery. Sociodemographic risk factors for obesity in the IBD population are similar to those in the general population. (Inflamm Bowel Dis 2010;)


Inflammatory Bowel Diseases | 2011

ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network

Wallace Crandall; Mph Michael D. Kappelman Md; Richard B. Colletti; Ian Leibowitz; John Grunow; Sabina Ali; Howard I. Baron; James Berman; Brendan Boyle; Stanley A. Cohen; Fernando del Rosario; Lee A. Denson; Lynn Duffy; Mark Integlia; Sandra C. Kim; David E. Milov; Ashish S. Patel; Bess T. Schoen; Dorota Walkiewicz; Peter A. Margolis

&NA; There is significant variation in diagnostic testing and treatment for inflammatory bowel disease. Quality improvement science methods can help address unwarranted variations in care and outcomes. Methods: The ImproveCareNow Network was established under the sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the American Board of Pediatrics as a prototype for a model of improving subspecialty care that included three components: 1) creating enduring multicenter collaborative networks of pediatric subspecialists, 2) sharing of performance data collected in patient registries, and 3) training in quality improvement. The network began with a focus on improving initial diagnostic testing and evaluation, the classification of the severity and extent of disease, the detection and treatment of inadequate nutrition and growth, and the appropriate dosing of immunomodulator medications. Changes are based on an evidence‐based model of chronic illness care involving the use of patient registries for population management, previsit planning, decision support, promoting self‐management, and auditing of care processes. Results: Currently, patients are being enrolled at 23 sites. Through 2009, data have been analyzed on over 2500 patients from over 7500 visits. Initial results suggest improvements in both care processes (e.g., appropriate medication dosing and completion of a classification bundle that includes the patients diagnosis, disease activity, distribution and phenotype, growth status, and nutrition status) and outcomes (e.g., the percentage of patients in remission). Conclusions: These improvements suggest that practice sites are learning how to apply quality improvement methods to improve the care of patients. (Inflamm Bowel Dis 2011;)


Pediatrics | 2006

Successful Wireless Capsule Endoscopy for a 2.5-Year-Old Child: Obscure Gastrointestinal Bleeding From Mixed, Juvenile, Capillary Hemangioma-Angiomatosis of the Jejunum

Hymie Kavin; James Berman; Thomas L. Martin; Ansley Feldman; Kimberly Forsey-Koukol

The lesion responsible for obscure gastrointestinal bleeding in the pediatric population may not be determined with standard primary endoscopic methods. Wireless capsule endoscopy, now a first-line modality for evaluation of the small bowel in the adult population, is a tool that may be useful among children. We report a case of a 2.5-year-old girl who presented with melenic stools. Upper and lower endoscopy, Meckel scans, and mesenteric angiography yielded negative results. Wireless capsule endoscopy identified numerous abnormal, dilated, blood vessels in the proximal jejunum, with associated fresh blood. The patient underwent surgical exploration, with resection of the affected portion of the jejunum. Pathologically, the dilated blood vessels were consistent with mixed, juvenile, capillary hemangioma-angiomatosis of developmental or congenital origin. The patient fared well postoperatively, with no additional bleeding in 9 months of follow-up monitoring. This case report highlights the use of capsule endoscopy in the diagnosis and successful treatment of gastrointestinal bleeding in a young infant. This is the youngest reported patient treated with the use of wireless capsule endoscopy in the pediatric population.


Pediatrics | 2014

Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System

Christopher B. Forrest; Wallace Crandall; L. Charles Bailey; Peixin Zhang; Marshall M. Joffe; Richard B. Colletti; Jeremy Adler; Howard I. Baron; James Berman; Fernando del Rosario; Andrew B. Grossman; Edward J. Hoffenberg; Esther J. Israel; Sandra C. Kim; Jenifer R. Lightdale; Peter A. Margolis; Keith Marsolo; Devendra I. Mehta; David E. Milov; Ashish S. Patel; Jeanne Tung; Michael D. Kappelman

OBJECTIVES: ImproveCareNow (ICN) is the largest pediatric learning health system in the nation and started as a quality improvement collaborative. To test the feasibility and validity of using ICN data for clinical research, we evaluated the effectiveness of anti-tumor necrosis factor-α (anti-TNFα) agents in the management of pediatric Crohn disease (CD). METHODS: Data were collected in 35 pediatric gastroenterology practices (April 2007 to March 2012) and analyzed as a sequence of nonrandomized trials. Patients who had moderate to severe CD were classified as initiators or non-initiators of anti-TNFα therapy. Among 4130 patients who had pediatric CD, 603 were new users and 1211 were receiving anti-TNFα therapy on entry into ICN. RESULTS: During a 26-week follow-up period, rate ratios obtained from Cox proportional hazards models, adjusting for patient and disease characteristics and concurrent medications, were 1.53 (95% confidence interval [CI], 1.20–1.96) for clinical remission and 1.74 (95% CI, 1.33–2.29) for corticosteroid-free remission. The rate ratio for corticosteroid-free remission was comparable to the estimate produced by the adult SONIC study, which was a randomized controlled trial on the efficacy of anti-TNFα therapy. The number needed to treat was 5.2 (95% CI, 3.4–11.1) for clinical remission and 5.0 (95% CI, 3.4–10.0) for corticosteroid-free remission. CONCLUSIONS: In routine pediatric gastroenterology practice settings, anti-TNFα therapy was effective at achieving clinical and corticosteroid-free remission for patients who had Crohn disease. Using data from the ICN learning health system for the purpose of observational research is feasible and produces valuable new knowledge.


Canadian Journal of Gastroenterology & Hepatology | 2017

Detailed histologic evaluation of eosinophilic esophagitis in pediatric patients presenting with dysphagia or abdominal pain and comparison of the histology between the two groups

Thirumazhisai S. Gunasekaran; Christopher Chu; Nemencio R. Ronquillo; Rohini Chennuri; Brian P. Adley; Kristina R. Borgen; Alan Schwartz; Robert Newberry; James Berman

EoE in children presents with four main symptoms. Most common symptoms exhibited by our clinic population are dysphagia (D) and abdominal pain (AP). Despite similar treatments, we found in an earlier study that the outcomes between these two groups were different. Therefore, we investigated if there exist any histological differences between these groups that could further our knowledge of EoE. Aim. To compare esophageal histology in detail, apart from the eosinophil count, between EoE-D and EoE-AP. Method. Biopsies of patients with EoE-D and EoE-AP were reevaluated for 10 additional histological criteria, in addition to the eosinophil count. Results. Both groups had 67 patients; peak mean eosinophil was 33.9 and 31.55 for EoE-D and EoE-AP (p < 0.05). Eosinophilic microabscesses, superficial layering of eosinophils, and epithelial desquamation were twice as common and significant in EoE-D group than EoE-AP. Eosinophil distribution around rete pegs was also significantly higher in EoE-D group. The remaining criteria were numerically higher in EoE-D, but not significant, with the exception of rete peg elongation. Conclusion. EoE-D patients have significantly higher eosinophils compared to EoE-AP, and the level of inflammation as seen from eosinophil microabscesses, superficial layering, desquamation, and the distribution around rete pegs is significantly higher.


Journal of Pediatric Gastroenterology and Nutrition | 2016

Continuous 48-hour Wireless Esophageal ph Monitoring in Children: Comparison Between Days 1 and 2.

Anupama Ravi; Thirumazhisai S. Gunasekaran; James Berman

Aim: Comparison of days 1 and 2 to each other and to the total recording of 48 hours in continuous 48-hour wireless esophageal pH monitoring in children. Methods: A retrospective study of 105 patients who underwent 48-hour pH monitoring (Bravo) studies between January 1992 and June 2010 was performed. Reflux variables were compared between days 1 and 2. Results: A total of 58 (55.2%) patients were men. The number of reflux episodes, number of long reflux >5 minutes, duration of the longest reflux (minutes), time pH <4 (minutes), fraction time pH <4 supine (%), fraction time pH <4 upright (%), reflux index, and DeMeester score did not differ between days 1 and 2. Conclusions: No effect of anesthesia was observed on the gastroesophageal reflux parameters on children.


International Journal of Pediatrics and Adolescent Medicine | 2016

Esophageal perforation: An uncommon initial manifestation of eosinophilic esophagitis

Thirumazhisai S. Gunasekaran; James Berman; Jennifer E. Lim-Dunham

EoE-Perforation: Eosinophilic esophagitis (EoE) is commonly observed in children and young adults. Common manifestations of EoE include dysphagia and food impaction in adolescents and adults, whereas children present with failure to thrive, regurgitation, or heartburn and abdominal pain. We describe two patients presenting with esophageal perforation and EoE. Diagnosing perforation promptly is critical to minimize and/or to avoid the multitude of complications resulting from esophageal perforation and to treat EoE because if left untreated, this condition may result in the recurrence of perforation, major morbidity, or rarely death.


Journal of Pediatric Gastroenterology and Nutrition | 2018

Proton Pump Inhibitors May Not Be the First Line of Treatment for GERD in Infants

Thirumazhisai S. Gunasekaran; Samir Kakodkar; James Berman


Gastroenterology | 2018

Tu1985 - Eosinophilic Esophagitis: Correlation of Improvement in Dysphagia with Eosinophils and Additional Eosinophilic Inflammation

Mohamed Rizwan Haroon Al Rasheed; Snehal Sonawane; Vijayalakshmi Kory; Alan Schwartz; James Berman; Thirumazhisai S. Gunasekaran


American Journal of Clinical Pathology | 2018

299 In-Depth Histological Analysis of Eosinophilic Esophagitis, With and Without Food Impaction: Outcome and Lessons Learned From 101 Adolescents

Snehal Sonawane; Mohamed Rizwan Haroon Al Rasheed; Vijayalakshmi Kory; Alan Schwartz; James Berman; Thirumazhisai S. Gunasekaran

Collaboration


Dive into the James Berman's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alan Schwartz

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Kiranmai Gorla

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Ashish S. Patel

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sandra C. Kim

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Wallace Crandall

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge